Poly(glycerol methacrylate)-based degradable nanoparticles for delivery of small interfering RNA

Pharmaceutical Development and Technology

Volumn 23, Issue 4, 2018, Pages 387-399

  Morsi, Noha G ^a   Ali, Shimaa M ^a   Elsonbaty, Sherouk S ^a   Afifi, Ahmed A ^a   Hamad, Mostafa A ^b   Gao, Hui ^c   Elsabahy, Mahmoud ^a,d,e,f  

^a ASSIUT UNIVERSITY   (Egypt)

^b Assiut University Faculty of Medicine   (Egypt)

^c TIANJIN UNIVERSITY OF TECHNOLOGY   (China)

^d TEXAS A AND M UNIVERSITY   (United States)

^e Assiut University   (Egypt)

^f MISR UNIVERSITY FOR SCIENCE AND TECHNOLOGY   (Egypt)

Author keywords

Biodegradable nanoparticles; chitosan; poly(glycerol methacrylate); polyethylenimine; siRNA

Indexed keywords

CHITOSAN NANOPARTICLE; DRUG CARRIER; NANOPARTICLE; NITROGEN; PHOSPHATE; POLY(GLYCEROL METHACRYLATE); POLYETHYLENEIMINE; POLYMER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; GLYCEROL; METHACRYLIC ACID; POLYGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SAFETY; DRUG STABILITY; FREEZE DRYING; HUH-7 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; CHEMISTRY; GENETIC TRANSFECTION; HUMAN; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; GLYCEROL; HUMANS; METHACRYLATES; MICE; NANOPARTICLES; POLYETHYLENEIMINE; POLYMERS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 85017191271     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.1080/10837450.2017.1312443     Document Type: Article

References (43)

1. Abbasi S, Paul A, Prakash S., 2011. Investigation of siRNA-loaded polyethylenimine-coated human serum albumin nanoparticle complexes for the treatment of breast cancer. Cell Biochem Biophys. 61:277–287.
2. Alameh M, Dejesus D, Jean M, Darras V, Thibault M, Lavertu M, Buschmann MD, Merzouki A. 2012. Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery. Int J Nanomedicine. 7:1399–1414.
3. Buschmann MD, Merzouki A, Lavertu M, Thibault M, Jean M, Darras V., 2013. Chitosans for delivery of nucleic acids. Adv Drug Deliv Rev. 65:1234–1270.
4. de Lima JM, Sarmento RR, de Souza JR, Brayner FA, Feitosa APS, Padilha R, Alves LC, Porto IJ, Batista RFBD, de Oliveira JE, et al. 2015. Evaluation of hemagglutination activity of chitosan nanoparticles using human erythrocytes. Biomed Res Int. 2015:247965.
5. DePass LR., 1989. Alternative approaches in median lethality (LD50) and acute toxicity testing. Toxicol Lett. 49:159–170.
6. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T., 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498.
7. Elsabahy M, Heo GS, Lim SM, Sun G, Wooley KL., 2015. Polymeric nanostructures for imaging and therapy. Chem Rev. 115:10967–11011.
8. Elsabahy M, Nazarali A, Foldvari M., 2011. Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv. 8:235–244.
9. Elsabahy M, Samarajeewa S, Raymond JE, Clark C, Wooley KL., 2013a. Shell-crosslinked knedel-like nanoparticles induce lower immunotoxicity than their non-crosslinked analogs. J Mater Chem B. 39:5241–5255.
10. Elsabahy M, Shrestha R, Clark C, Taylor S, Leonard J, Wooley KL., 2013b. Multifunctional hierarchically assembled nanostructures as complex stage-wise dual-delivery systems for coincidental yet differential trafficking of siRNA and paclitaxel. Nano Lett. 13:2172–2181.
11. Elsabahy M, Wazen N, Puxan N, Deleavey G, Servant M, Damha MJ, Leroux J-C., 2009. Delivery of nucleic acids through the controlled disassembly of multifunctional nanocomplexes. Adv Funct Mater. 19:3862–3867.
12. Elsabahy M, Wooley KL., 2012. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 41:2545–2561.
13. Elsabahy M, Wooley KL., 2013. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev. 42:5552–5576.
14. Elsabahy M, Wooley KL., 2015. Data mining as a guide for the construction of cross-linked nanoparticles with low immunotoxicity via control of polymer chemistry and supramolecular assembly. Acc Chem Res. 48:1620–1630.
15. Elsabahy M, Zhang M, Gan SM, Waldron KC, Leroux JC., 2008. Synthesis and enzymatic stability of PEGylated oligonucleotide duplexes and their self-assemblies with polyamidoamine dendrimers. Soft Matter. 4:294–302.
16. Elsabahy M, Zhang S, Zhang F, Deng ZJ, Lim YH, Wang H, Parsamian P, Hammond PT, Wooley KL, et al. 2013c. Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles. Sci Rep. 3:3313.
17. Elzeny H, Zhang F, Ali EN, Fathi HA, Zhang S, Li R, El-Mokhtar MA, Hamad MA, Wooley KL, Elsabahy M. 2017. Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA. Drug Des Dev Ther. 11:483–496.
18. Felber AE, Castagner B, Elsabahy M, Deleavey GF, Damha MJ, Leroux JC., 2011. siRNA nanocarriers based on methacrylic acid copolymers. J Control Release. 152:159–167.
19. Gao H, Elsabahy M, Giger EV, Li D, Prud'homme RE, Leroux JC., 2010. Aminated linear and star-shape poly(glycerol methacrylate)s: synthesis and self-assembling properties. Biomacromolecules. 11:889–895.
20. Gu HR, Park SC, Choi SJ, Lee JC, Kim YC, Han CJ, Kim J, Yang KY, Kim YJ, Noh GY, et al. 2015. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells. Clin Mol Hepatol. 21:49–59.
21. Gujrati M, Malamas A, Shin T, Jin E, Sun Y, Lu ZR., 2014. Multifunctional cationic lipid-based nanoparticles facilitate endosomal escape and reduction-triggered cytosolic siRNA release. Mol Pharm. 11:2734–2744.
22. Guo P, Gu W, Chen Q, Lu H, Han X, Li W, Gao H., 2015. Dual functionalized amino poly(glycerol methacrylate) with guanidine and Schiff-base linked imidazole for enhanced gene transfection and minimized cytotoxicity. J Mater Chem B Mater Biol Med. 3:6911–6918.
23. Han X, Chen Q, Lu H, Ma J, Gao H., 2015. Probe intracellular trafficking of a polymeric DNA delivery vehicle by functionalization with an aggregation-induced emissive tetraphenylethene derivative. ACS Appl Mater Interfaces. 7:28494–28501.
24. Harada-Shiba M, Yamauchi K, Harada A, Takamisawa I, Shimokado K, Kataoka K., 2002. Polyion complex micelles as vectors in gene therapy—pharmacokinetics and in vivo gene transfer. Gene Ther. 9:407–414.
25. Haroon MM, Dar GH, Jeyalakshmi D, Venkatraman U, Saba K, Rangaraj N, Patel AB, Gopal V., 2016. A designed recombinant fusion protein for targeted delivery of siRNA to the mouse brain. J Control Release. 228:120–131.
26. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MØ, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F, et al. 2006. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther. 14:476–484.
27. Juliano R, Bauman J, Kang H, Ming X., 2009. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm. 6:686–695.
28. Li C, Yang YW, Liang ZX, Wu GL, Gao H., 2013. Post-modification poly(glycidyl methacrylate)s with alkyl amine and isothiocyanate for effective pDNA delivery. Polym Chem. 4:4366–4374.
29. Li QL, Gu W, Gao H, Yang YW., 2014. Self-assembly and applications of poly(glycidyl methacrylate)s and their derivatives. Chem Commun (Camb). 50:13201–13215.
30. Liang Z, Wu X, Yang YW, Li C, Wu G, Gao H., 2013. Quaternized amino poly(glycerol-methacrylate)s for enhanced pDNA delivery. Polym Chem. 4:3514–3523.
31. Man DK, Chow MY, Casettari L, Gonzalez-Juarrero M, Lam JK., 2016. Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. Adv Drug Deliv Rev. 102:21–32.
32. Miller LC, Tainter M., 1944. Estimation of the ED50 and its error by means of logarithmic-probit graph paper. Exp Biol Med. 57:261–264.
33. Nimesh S, Chandra R., 2009. Polyethylenimine nanoparticles as an efficient in vitro siRNA delivery system. Eur J Pharm Biopharm. 73:43–49.
34. Nimesh S., 2012. Polyethylenimine as a promising vector for targeted siRNA delivery. Curr Clin Pharmacol. 7:121–130.
35. Parsel SM, Grandis JR, Thomas SM., 2016. Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene. 35:3217–3226.
36. Ragelle H, Vandermeulen G, Préat V., 2013. Chitosan-based siRNA delivery systems. J Control Release. 172:207–218.
37. Sato Y, Note Y, Maeki M, Kaji N, Baba Y, Tokeshi M, Harashima H., 2016. Elucidation of the physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery. J Control Release. 229:48–57.
38. Shevchenko VD, Salakhieva DV, Yergeshov AA, Badeev YV, Shtyrlin YG, Abdullin TI., 2016. Propoxylation of cationic polymers provides a novel approach to controllable modulation of their cellular toxicity and interaction with nucleic acids. Mater Sci Eng C Mater Biol Appl. 69:60–67.
39. Shrestha R, Elsabahy M, Florez-Malaver S, Samarajeewa S, Wooley KL., 2012. Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities. Biomaterials. 33:8557–8568.
40. Singh MS, Peer D., 2016. RNA nanomedicines: the next generation drugs? Curr Opin Biotechnol. 39:28–34.
41. Van den Heuvel M, Clark D, Fielder R, Koundakjian PP, Oliver GJ, Pelling D, Tomlinson NJ, Walker AP., 1990. The international validation of a fixed-dose procedure as an alternative to the classical LD50 test. Food Chem Toxicol. 28:469–482.
42. Whitehead KA, Langer R, Anderson DG., 2009. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 8:129–138.
43. Xue HY, Liu S, Wong HL., 2014. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond). 9:295–312.